氨甲环酸与ε-氨基己酸在全关节置换术中的随机对照试验
这项前瞻性随机对照试验在单个三级转诊中心纳入235例(90例全髋、145例全膝)关节置换患者,术中分两次给予氨甲环酸(TXA,n=119)或ε-氨基己酸(EACA,n=116)。全膝关节置换中EACA组引流血量、血容量丢失及血红蛋白变化均大于TXA组,全髋关节置换无统计学显著差异,两组输血率无显著差异。
要点
- 全膝关节置换中EACA组引流血量中位数320ml高于TXA组158ml(p<0.001)。
- 全膝关节置换中EACA组血容量丢失中位数891ml高于TXA组661ml(p=0.014)。
- 全髋与全膝置换中两组术后并发症数量与类型及住院时长均无统计学显著差异。
核心结论
- 在全髋和全膝关节置换术中,EACA与TXA相比围手术期失血量增加,但输血率无显著差异。
- 作者表示目前推荐骨科医生根据费用和区域可及性选择抗纤溶药物。
研究设计与样本
- 前瞻性随机对照试验,在单个三级转诊中心纳入235例患者(90例全髋关节置换、145例全膝关节置换)。
- 全髋队列女性占53.3%,中位年龄59.8岁(IQR 53.3至68.1);全膝队列女性占63.4%,中位年龄65.1岁(IQR 59.4至69.5)。
- 患者术中分两次接受TXA(n=119)或EACA(n=116)。
主要发现
- 全膝关节置换中EACA组引流血量中位数320ml(IQR 185至420)vs TXA组158ml(IQR 110至238),p<0.001。
- 全膝关节置换中EACA组血容量丢失中位数891ml(IQR 612至1203)vs TXA组661ml(IQR 514至980),p=0.014。
- 全膝关节置换中EACA组血红蛋白较术前变化中位数2.1ml(IQR 1.7至2.8)vs TXA组1.9ml(IQR 1.2至2.4),p=0.016。
- 全髋关节置换队列中任何血液学结局指标均未观察到统计学显著差异。
- EACA组有1例患者需要输血,TXA组无患者需要输血;全髋和全膝置换中两组术后并发症数量与类型及住院时长均无统计学显著差异。
临床怎么用
- 作者推荐骨科医生根据费用和区域可及性选择抗纤溶药物。
局限性
- 原文结论指出需要进一步的前瞻性研究来比较每种药物的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Antifibrinolytic agents, including tranexamic acid (TXA) and epsilon-aminocaproic acid (EACA), have been shown to be safe and effective for decreasing perioperative blood loss and transfusion following total hip arthroplasty (THA) and total knee arthroplasty (TKA). However, there are few prospective studies that directly compare these agents. The purpose of this study was to compare the benefits of intraoperative intravenous TXA with EACA. PATIENTS AND METHODS: A total of 235 patients (90 THA and 145 TKA) were enrolled in this prospective, randomized controlled trial at a single tertiary-care referral centre. In the THA cohort, 53.3% of the patients were female with a median age of 59.8 years (interquartile range (IQR) 53.3 to 68.1). In the TKA cohort, 63.4% of the patients were female with a median age of 65.1 years (IQR 59.4 to 69.5). Patients received either TXA (n = 119) or EACA (n = 116) in two doses intraoperatively. The primary outcome measures included change in haemoglobin level and blood volume, postoperative drainage, and rate of transfusion. Secondary outcome measures included postoperative complications, cost, and length of stay (LOS). RESULTS: TKA patients who received EACA had greater drainage (median 320 ml (IQR 185 to 420) vs 158 ml (IQR 110 to 238); p < 0.001), increased loss of blood volume (891 ml (IQR 612 to 1203) vs 661 ml (IQR 514 to 980); p = 0.014), and increased haemoglobin change from the preoperative level (2.1 ml (IQR 1.7 to 2.8) vs 1.9 ml (IQR 1.2 to 2.4); p = 0.016) compared with patients who received TXA. For the THA cohort, no statistically significant differences were observed in any haematological outcome measure. One patient in the EACA group required transfusion. No patient in the TXA group required transfusion. There were no statistically significant differences in number or type of postoperative complications or LOS for either THA or TKA patients regardless of whether they received TXA or EACA. CONCLUSION: For hip and knee arthroplasty procedures, EACA is associated with increased perioperative blood loss compared with TXA. However, there is no significant difference in transfusion rate. While further prospective studies are needed to compare the efficacy of each agent, we currently recommend orthopaedic surgeons to select their antifibrinolytic based on cost and regional availability. Cite this article: Bone Joint J 2019;101-B:1093-1099.
引用
- Bradley KE, Ryan SP, Penrose CT, et al. Tranexamic acid or epsilon-aminocaproic acid in total joint arthroplasty? A randomized controlled trial. Bone Joint J. 2019. PMID: 31474134. doi:10.1302/0301-620X.101B9.BJJ-2018-1096.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。